| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Monica Galli | |
| P2860 | cites work | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 |
| Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 | ||
| VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632982 | ||
| Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| Management of the antiphospholipid syndrome | Q33423034 | ||
| Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. | Q33576496 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| Origin of antiphospholipid antibodies. | Q34354708 | ||
| Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients | Q34435380 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome | Q35158386 | ||
| Pathophysiology of the antiphospholipid antibody syndrome | Q35309024 | ||
| Long term outcome of catastrophic antiphospholipid syndrome survivors | Q35552789 | ||
| Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation | Q81712990 | ||
| A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis | Q81831105 | ||
| Antibody profiles for the diagnosis of antiphospholipid syndrome | Q81873167 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study | Q84302565 | ||
| The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study | Q84438431 | ||
| Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. | Q35895238 | ||
| Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. | Q36609700 | ||
| Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus | Q37158591 | ||
| The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis | Q37721612 | ||
| Towards evidence-based treatment of thrombotic antiphospholipid syndrome | Q37721614 | ||
| Obstetric antiphospholipid syndrome | Q37946086 | ||
| Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? | Q38089684 | ||
| Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab | Q38115382 | ||
| The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours? | Q38497348 | ||
| Toll-like receptors play a crucial part in the pathophysiological activity of antiphospholipid antibodies | Q38497394 | ||
| Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis? | Q38518822 | ||
| Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury | Q39692566 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome | Q43246259 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients | Q43519903 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients | Q44830352 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis | Q45126748 | ||
| CAPS Registry | Q45230040 | ||
| Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". | Q45780878 | ||
| Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. | Q45822025 | ||
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. | Q50619255 | ||
| Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. | Q51158264 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Antiphospholipid syndrome | Q55891386 | ||
| Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients | Q56907610 | ||
| Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS) | Q57624052 | ||
| Induction of anti-β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes | Q57983447 | ||
| High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies | Q61837677 | ||
| Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach | Q61837755 | ||
| Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin | Q67866864 | ||
| Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies | Q67939879 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease | Q68091809 | ||
| Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH | Q70897451 | ||
| Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry | Q71112355 | ||
| Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor | Q73139455 | ||
| Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C | Q74270308 | ||
| The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity--discrimination between functional and non-functional anti-prothrombin-antibodies | Q74503076 | ||
| Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study | Q78505085 | ||
| Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity | Q80213989 | ||
| Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus | Q81168201 | ||
| Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy | Q81232007 | ||
| Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change | Q81441260 | ||
| Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C | Q81620372 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 1-7 | |
| P577 | publication date | 2013-12-22 | |
| P1433 | published in | Autoimmunity highlights | Q26853848 |
| P1476 | title | Treatment of the antiphospholipid syndrome. | |
| P478 | volume | 5 |
| Q49968681 | Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome | cites work | P2860 |
Search more.